Skip to main content

Branded

  • Lilly names new VP oncology research

    INDIANAPOLIS — Eli Lilly on Thursday announced that it has named Greg Plowman VP oncology research and SVP for ImClone Systems research.

    Plowman will oversee the oncology research efforts of both Lilly and ImClone, the drug maker's subsidiary that it acquired in 2008. He will report to Jan Lundberg, EVP science and technology and Lilly Research Labs president, as well as Bernhard Ehmer, ImClone president.

    Prior to accepting the position at Lilly, Plowman served as senior director of research for Genentech for six years. He officially will join the company March 28.

  • Merck seeks FDA approval for Saflutan

    WHITEHOUSE STATION, N.J. — The Food and Drug Administration has accepted an approval application from Merck for a drug to treat eye diseases, Merck said Wednesday.

    Merck is seeking approval for Saflutan (tafluprost) ophthalmic solution, an investigational drug for relieving eye pressure in patients with glaucoma and ocular hypertension.

  • Purdue offers grant to fund Fla. Rx monitoring program

    STAMFORD, Conn. — Drug maker Purdue Pharma is giving a $1 million grant to the state of Florida to help fund the state’s prescription drug monitoring program, the company said Wednesday.

    Purdue said the program was designed to combat illegal diversion and abuse of prescription drugs. Purdue is the maker of OxyContin (oxycodone), an extended-release opioid painkiller that often is a target of abuse.

  • Tris seeks FDA OK for allergy treatment for kids

    MONMOUTH JUNCTION, N.J. — The Food and Drug Administration has accepted a regulatory approval application from Tris Pharma for a drug to treat allergies in children ages 2 years and older, Tris said Wednesday.

    Tris said that if approved, its carbinoxamine extended-release oral suspension would provide an alternative to currently available immediate-release formulations.

  • Lilly head continues call for medical innovation

    TOKYO — Eli Lilly leader John Lechleiter has become something of an evangelist for medical innovation lately.

    On Wednesday, the Lilly chairman, president and CEO spoke to the U.S./Japan Business Council in Tokyo to call for changes and policies in the biopharmaceutical industry that encourage innovation, or “reinventing invention,” as he called it.

  • Pyott steps in as Allergan's president

    IRVINE, Calif. — Allergan reappointed David Pyott as president earlier this week, adding to his role as chairman and CEO. Pyott will succeed Michael Ball, who has accepted the position of CEO at Hospira, a specialty pharmaceutical and medication delivery company, Allergan reported.

    The changeover takes place March 27.

  • Salix issued CRL for Xifaxan

    RALEIGH, N.C. — The Food and Drug Administration declined to approve a drug made by Salix Pharmaceuticals for irritable bowel syndrome, Salix said Tuesday.

    The FDA issued a complete response letter to Salix for Xifaxan (rifaximin), a treatment for nonconstipation IBS and IBS-related bloating. Salix said it had anticipated that it would receive the letter based on an understanding that the agency needed more information related to retreatment.

  • New diabetes drug accepted for review by FDA

    PRINCETON, N.J. — The Food and Drug Administration has accepted a regulatory approval application for a Type 2 diabetes drug from Bristol-Myers Squibb and AstraZeneca, the two drug makers said Tuesday.

    The FDA accepted the application for dapagliflozin, an investigational drug for adults with the disease. The Centers for Disease Control and Prevention estimated that 1-in-11 U.S. adults has diabetes, with 90% to 95% of them having Type 2 diabetes.

    The agency expects to take action on the application in late October.

X
This ad will auto-close in 10 seconds